Clinical Trial: Sonlicromanol in Post-COVID: A Randomized, Double-blind, Placebo-controlled, Phase II Trial

U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07298005) titled 'Sonlicromanol in Post-COVID: A Randomized, Double-blind, Placebo-controlled, Phase II Trial' on Dec. 11.

Brief Summary: The aim of this randomized, doube-blind, placebo-controlled, phase II trial, is to study the effect of sonlicromanol on fatigue in patient with post-COVID who experience post-exertional malaise (PEM).

Study Start Date: Feb., 2026

Study Type: INTERVENTIONAL

Condition: Post COVID Condition

Intervention: DRUG: Sonlicromanol

Sonlicromanol 90mg bid for 13 weeks

DRUG: Placebo

Placebo bid for 13 weeks

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Michele van Vugt

Information provided by (Responsible Party): ...